News & Press Releases | Vector Science (TSXV: PAIN)

October 15, 2026 Press Release

Vector Science & Therapeutics Corp. Appoints Russell Starr as President

Vector Science & Therapeutics Corp. (TSXV: PAIN) (the "Company") today announced the appointment of Russell Starr as President of the Company, effective October 5, 2026. Bill Jackson will continue to serve as Chief Executive Officer. In connection with his appointment, Mr. Starr has, subject to the receipt of all required approvals of the TSX Venture Exchange, elected to take his full salary in common shares of the Company, and any incentive securities granted to him will be performance-based.

October 13, 2026 Press Release

Collaboration and SAFE Investment in Whoopi Wellness, Inc.

Vector has made an investment in Whoopi Wellness through a Simple Agreement for Future Equity (SAFE). The companies plan to work together on peptide-based products for women’s wellness using peptides formulated and manufactured by Vector. Vector only uses peptides that have been tested using validated analytical testing to ensure purity, potency, endotoxin levels and sterility. Whoopi Wellness is committed to high-quality, safe, rigorously tested peptides in its products.

August 24, 2026 Press Release

Vector Science & Therapeutics (TSXV: PAIN) Begins Peptide Production as First Suite at LyoGenesis Manufacturing Comes Online

* 55,000 vials of peptides will be produced from this production suite and are pre-sold * Milestone facility meets cGMP, FDA, and ISO quality standards on schedule; remaining three suites to launch in September

August 20, 2026 Press Release

Verlytix Launches as a Related Company to LyoGenesis Manufacturing

Verlytix is applying its analytical and quality testing capabilities to peptide testing in support of Vector Science & Therapeutics, alongside its existing pharmaceutical testing business

August 17, 2026 Press Release

Vector Science and Therapeutics Corp. Signs Amended, 10-Year Manufacturing and Testing Agreement with LyoGenesis Holdings

Vector Science and Therapeutics Corp. has signed an amended, 10-year exclusive manufacturing and testing agreement with LyoGenesis Holdings LLC. Effective August 13, 2026, this contract secures U.S.-based, cGMP-compliant manufacturing capacity for Vector’s proprietary lyophilized peptide platform.

July 24, 2026 Press Release

Vector Science & Therapeutics Reports First Quarterly Financial Results as a Public Company; Announces Inaugural Investor Q&A on July 28

Vector Science & Therapeutics Corp. (TSXV: PAIN) today announced the filing of its first quarterly financial statements and Management’s Discussion & Analysis since completing its going-public reverse takeover with OpenSesame Acquisition Corp. on April 23, 2026, and announced its inaugural quarterly investor Q&A, held via Microsoft Teams on July 28, 2026.

July 21, 2026 Press Release

Vector Science & Therapeutics Announces Distributor Network Buildout to Support Its Peptide Portfolio Across Orthopedic, Sports, and Regenerative Medicine Channels

Vector Science & Therapeutics Corp. (TSXV: PAIN) ("Vector" or the "Company") today announced plans to build a dedicated distributor network to support commercialization of its peptide portfolio across the orthopedic, sports, and regenerative medicine channels, focused on musculoskeletal conditions, soft tissue injury, and degenerative joint disease, including osteoarthritis.

July 17, 2026 Press Release

Vector Science & Therapeutics and Caresyntax Announce Real-World Evidence Partnership for VectorMist

Vector Science & Therapeutics Corp. (TSXV: PAIN) ("Vector") and Caresyntax, a global leader in surgical intelligence and real-world evidence, today announced a strategic partnership to build the clinical evidence infrastructure supporting VectorMist™, Vector’s localized atomized drug delivery platform, and The LASSO Protocol™ (Laparoscopic Atomization System for Sparing Opioids).

July 15, 2026 Press Release

Vector Science & Therapeutics Builds 15-Patent-Application Intellectual Property Portfolio Around Precision Therapeutic Delivery, Anchored by Peptide and Biologic Administration Technologies

Vector Science & Therapeutics, Corp. (TSXV: PAIN) ("Vector" or the "Company") today announced the expansion of its intellectual property portfolio to 15 patent applications developed and filed over approximately the past two years, establishing a broad technology estate centered on delivering therapeutic agents — including peptides and other biologics that are frequently difficult to administer outside the gastrointestinal tract — to the right tissue, at the right concentration, for the appropriate duration of treatment.

July 7, 2026 Press Release

Vector Science & Therapeutics Announces Landmark Exclusive cGMP Manufacturing Agreement with LyoGenesis Plus for Its Proprietary Peptide Portfolio

Vector Science & Therapeutics Corp. (TSXV: PAIN) ("Vector" or the "Company") today announced an exclusive licensing and manufacturing agreement with LyoGenesis Plus, a cGMP lyophilization and manufacturing partner based in Mequon, Wisconsin, under which Vector licenses its proprietary biomechanical peptide delivery platform to LyoGenesis in exchange for an exclusive, long-term manufacturing relationship covering its proprietary peptide portfolio.

June 30, 2026 Press Release

Vector Science & Therapeutics Files Provisional Patent for Breakthrough Transdermal Peptide Delivery Platform

Vector Science & Therapeutics Corp. (TSXV: PAIN) today announced the filing of a provisional patent application covering a wearable transdermal peptide delivery platform designed to enable sustained, site-directed delivery of therapeutic peptides through the skin — without needles, systemic exposure, or gastrointestinal degradation.

May 13, 2026 Press Release

Vector Science & Therapeutics Agrees to an Option to Invest in LyoGenesis Plus, Securing Long-Term Access to FDA-Registered, cGMP Manufacturing

Vector Science & Therapeutics Corp. (TSXV: PAIN) has entered into an option agreement to acquire up to a 15% equity interest in LyoGenesis Plus for up to US$1,000,000, securing pharmaceutical-grade cGMP manufacturing access through an FDA-registered, 35,000 sq. ft. facility in Mequon, Wisconsin, to support its growing portfolio of 22 novel peptide formulations.

May 12, 2026 Press Release

Vector Science & Therapeutics Enters Three-Year Development and Manufacturing Agreement with MPP Group LLC

Vector Science & Therapeutics Corp. (TSXV: PAIN) has entered into a three-year development and manufacturing agreement with MPP Group LLC, a key milestone advancing the Company’s therapeutic delivery platform toward commercial-scale production.

May 1, 2026 Press Release

Vector Science & Therapeutics Files Provisional Patent for Novel Microneedle Catheter Platform for Intratumoral Drug Delivery

Vector Science & Therapeutics Corp. (TSXV: PAIN) announces the filing of a provisional patent application covering a novel microneedle catheter platform designed to enable precise, minimally invasive intratumoral drug delivery, advancing the Company’s site-directed therapeutic intervention portfolio.

April 30, 2026 Press Release

Vector Science & Therapeutics Announces Tommy Thompson as Chairman of the Board

Vector Science and Therapeutics Corp. (TSXV: PAIN) announces the appointment of Tommy Thompson — former U.S. Secretary of Health and Human Services and four-term Governor of Wisconsin — as Chairman of the Board of Directors, bringing decades of healthcare policy expertise and executive leadership to the company’s growing governance structure.

April 24, 2026 Press Release

Vector Science and Therapeutics Announces Listing on the TSX Venture Exchange

Vector Science and Therapeutics Corp. (TSXV: PAIN) announces the completion of its qualifying transaction and listing on the TSX Venture Exchange, marking a significant milestone in the company’s strategic development with access to Canadian public capital markets to advance its biomechanical and transdermal drug delivery platforms.

October 3, 2025 Press Release

Vector Science & Therapeutics Inc. to Reverse Merge with OpenSesame Acquisition Corp.

Vector Science & Therapeutics Inc. has entered into a definitive agreement for a reverse merger with OpenSesame Acquisition Corp., a significant step toward listing on the TSX Venture Exchange (TSXV).

News &Press Releases

News articles